Qube Research & Technologies (QRT)
DAWN

Qube Research & Technologies (QRT)’s Day One Biopharmaceuticals DAWN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.9M Buy
1,954,552
+467,990
+31% +$6.59M 0.05% 500
2025
Q4 		$13.9M Buy
1,486,562
+318,893
+27% +$2.66M 0.01% 1128
2025
Q3 		$8.23M Buy
1,167,669
+223,467
+24% +$1.54M 0.01% 1439
2025
Q2 		$6.14M Buy
944,202
+663,418
+236% +$4.56M 0.01% 1581
2025
Q1 		$2.23M Buy
280,784
+96,128
+52% +$1.04M ﹤0.01% 1913
2024
Q4 		$2.34M Buy
184,656
+94,468
+105% +$1.31M ﹤0.01% 1817
2024
Q3 		$1.26M Buy
90,188
+44,536
+98% +$635K ﹤0.01% 1944
2024
Q2 		$629K Buy
+45,652
New +$668K ﹤0.01% 2071
2023
Q2 		– Sell
-104,327
Closed -$1.39M – 2504
2023
Q1 		$1.39M Buy
104,327
+91,057
+686% +$1.78M 0.01% 1161
2022
Q4 		$286K Buy
+13,270
New +$272K ﹤0.01% 1669

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Qube Research & Technologies (QRT)'s DAWN Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Day One Biopharmaceuticals (DAWN) stake by 31% in Q1 2026, buying an estimated $6.59M and bringing the position to 1,954,552 shares worth $41.9M. The position accounts for 0.05% of the portfolio, ranked #500.

Qube Research & Technologies (QRT) first reported a position in DAWN in Q4 2022 and has held it in 10 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Qube Research & Technologies (QRT) held 1,954,552 shares of Day One Biopharmaceuticals worth $41.9M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 467,990 Day One Biopharmaceuticals shares in Q1 2026, an estimated $6.59M.
  • Day One Biopharmaceuticals made up 0.05% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #500 holding.
  • Qube Research & Technologies (QRT) first reported a position in Day One Biopharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.